Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma
Launched by THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL COLLEGE · Oct 27, 2024
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how uroepithelial carcinoma, a type of cancer that affects the urinary system, is currently diagnosed and treated in different hospitals in Henan Province. The study aims to gather information about the latest methods and practices used for treating this cancer, which can help improve patient care in the future.
To participate in this trial, adults aged 18 and older who have been diagnosed with uroepithelial carcinoma are eligible, whether they are newly diagnosed or have completed treatment for the early stages of the disease. Participants should have a complete medical history available, as this information is crucial for the study. It's important to note that the trial is not yet recruiting participants, so there will be no immediate actions required. If you or a family member are eligible and decide to participate in the future, you can expect to contribute to valuable research that may benefit others facing this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults ≥18 years of age (at enrollment)
- • Histologically confirmed uroepithelial carcinoma
- • Patients with newly diagnosed or completed radical uroepithelial carcinoma in the early stages of uroepithelial cancer/advanced unresectable or with distant metastases of urothelial carcinoma
- • Complete medical history information
- Exclusion Criteria:
- • Incomplete medical history and medical records
About The First Affiliated Hospital Of Xinxiang Medical College
The First Affiliated Hospital of Xinxiang Medical College is a leading clinical research institution dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary research, the hospital combines cutting-edge medical practices with academic rigor, ensuring that its clinical trials adhere to the highest ethical and scientific standards. The institution is committed to fostering a culture of excellence in research, providing state-of-the-art facilities and a diverse patient population, which enhances its capability to contribute significantly to the development of new therapeutic interventions and medical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Kaifeng, Henan, China
Luoyang, Henan, China
Nanyang, Henan, China
Puyang, Henan, China
Xinxiang, Henan, China
Xinxiang, Henan, China
Xinxiang, Henan, China
Xinxiang, Henan, China
Xinxiang, Henan, China
Xinxiang, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported